Scotiabank Maintains Sector Outperform on Alnylam Pharmaceuticals, Raises Price Target to $310
Portfolio Pulse from Benzinga Newsdesk
Scotiabank analyst Greg Harrison has maintained a Sector Outperform rating on Alnylam Pharmaceuticals and raised the price target from $305 to $310.
November 01, 2024 | 2:22 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Scotiabank has reaffirmed its positive outlook on Alnylam Pharmaceuticals by maintaining a Sector Outperform rating and slightly increasing the price target to $310.
The reaffirmation of a Sector Outperform rating and an increase in the price target by Scotiabank suggests a positive outlook for Alnylam Pharmaceuticals. This could lead to increased investor confidence and a potential rise in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100